NCT02961166

Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients

Intravenous Immunoglobulin Therapy in ARDS Patients With Extracorporeal Membrane Oxygenation (ECMO) Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 57 (actual)
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

57 patients with Adult Respiratory Distress Syndrome (ARDS) requiring Extracorporeal membrane oxygenation (ECMO) therapy were analyzed retrospectively. 28 patients had received immunglobulin M-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy. These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.

Detailed description

57 patients with ARDS requiring ECMO therapy were analyzed retrospectively. 28 patients had received IgM-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy. Patient characteristics, like Acute Physiology And Chronic Health Evaluation (APACHE) and Sepsis-related organ failure assessment (SAPS) Score, preexisting diseases, origin of infection, duration of ECMO therapy were analyzed in these patients. These patients were further analyzed regarding LOS ICU, LOS in hospital and regarding mortality.

Conditions

• Respiratory Distress Syndrome, Adult
• Septic Shock

Interventions

Type	Name	Description
DRUG	IgM enriched Immunoglobulins	Treatment for 3 days

Timeline

• Start date: 2012-01-01
• Primary completion: 2016-01-01
• Completion: 2016-05-01
• First posted: 2016-11-10
• Last updated: 2018-04-24

Locations

1 site across 1 country: Germany